BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects a mixed outlook: declining gross margins due to product mix and manufacturing issues, but a positive net income and ongoing product development. The Q&A highlights potential future benefits from new products and market expansion but also indicates current challenges with margins and no immediate synergies from recent agreements. The guidance for 2026 is cautiously optimistic but lacks strong short-term catalysts, resulting in a neutral sentiment for the stock price.
Key Financial Performance
Total Revenue $27.5 million, increasing 25% year-over-year. The increase was primarily related to increased sales of biopreservation media products, driven by strong demand from customers with commercially approved therapies as well as strong revenue growth from the balance of the product portfolio.
Adjusted EBITDA $6.2 million or 22% of revenue, up roughly 15% from the prior year. The primary driver of the change as a percentage of revenue in the current quarter was due to the impact of bag yields on gross margin percentage.
GAAP Gross Margin 64% compared with 67% in Q1 2025. The decrease can primarily be attributed to a product mix shift towards bags, which carry lower gross margins than bottles, as well as the impact from manufacturing yields.
Adjusted Gross Margin 64% compared with 68% in the prior year. The decrease is attributed to a product mix shift towards bags and the impact from manufacturing yields, which is considered transitory.
GAAP Operating Expenses $17.5 million versus $15.3 million in Q1 2025. The increase is attributed to a $1.2 million increase in R&D related to the PanTHERA acquisition and the opening of the Center of Excellence, as well as a $0.9 million increase in stock-based compensation acceleration related to severance, partially offset by a $0.8 million reduction in acquisition costs.
Adjusted Operating Expenses $16.8 million compared with $13.8 million in the prior year. The increase is due to higher R&D expenses and stock-based compensation acceleration related to severance.
GAAP Operating Income $27,000 versus an operating loss of $0.5 million in Q1 2025. The improvement was primarily due to increased revenue and lower acquisition costs, partially offset by higher stock compensation related to severance.
Adjusted Operating Income $1 million compared with $1.2 million in Q1 2025. The slight decrease is due to higher operating expenses.
GAAP Net Income $1.2 million or $0.02 per share in Q1 compared to $0.3 million or $0.01 per share in the prior year. The increase was primarily due to increased revenues.
Cash and Marketable Securities $111.5 million as of March 31, 2026, compared with $120.2 million as of December 31, 2025. The decrease was driven by tax obligations for share withholdings vested in Q1, debt principal payments, and unfavorable working capital, including an increase in accounts receivable.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Biopreservation Media (BPM): BPM remains the primary driver of revenue growth, representing over 85% of total revenue. It is widely adopted across commercial therapies and clinical pipelines, with a dominant market share. BPM products are embedded in 17 approved therapies, with visibility into 9 additional approvals and expanded indications over the next 12 months.
CellSeal Vials and hPL product lines: These products are utilized in 4 approved therapies and over 35 clinical programs. They are supporting cross-selling efforts and have the potential to increase revenue per dose by 2 to 3 times relative to BPM alone.
CGT Market Expansion: BioLife's solutions are utilized in over 250 commercially sponsored CGT clinical trials in the U.S., with a market share exceeding 70%, particularly in late-stage Phase III programs. The company is well-positioned to benefit from the expansion of therapies into new geographies and larger indications.
Revenue Growth: Total revenue for Q1 2026 reached $27.5 million, a 25% year-over-year increase, driven by BPM and other cell processing tools.
Gross Margin: GAAP gross margin for Q1 2026 was 64%, down from 67% in Q1 2025, due to a product mix shift and manufacturing yield issues. These issues are being addressed as a key operational priority.
Adjusted EBITDA: Adjusted EBITDA for Q1 2026 was $6.2 million, representing 22% of revenue, up 15% year-over-year.
Strategic M&A and Partnerships: The company is focused on selective acquisitions, minority investments, and strategic partnerships to broaden its platform and increase participation in the CGT ecosystem.
Capital Allocation: BioLife is prioritizing high-return opportunities for long-term growth, both organically and through strategic initiatives.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Gross Margin and Adjusted EBITDA Decline: Gross margin and adjusted EBITDA as a percentage of revenue declined year-over-year due to bag yield dynamics. This operational issue is a priority, but it remains unresolved and is impacting financial performance.
Product Mix Shift: A shift in product mix towards bags, which carry lower gross margins than bottles, has negatively impacted gross margins.
Manufacturing Yield Issues: Manufacturing yield issues related to bags are causing operational inefficiencies and are cited as a key challenge for 2026.
Increased Operating Expenses: Operating expenses increased year-over-year due to higher R&D costs from the PanTHERA acquisition and stock-based compensation acceleration related to severance.
Working Capital Challenges: Unfavorable working capital changes, including a significant increase in accounts receivable, have impacted cash flow.
Debt Obligations: The company faces a $2.5 million short-term debt balance with a $1.2 million balloon payment due in June 2026, which could strain financial resources.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Guidance: BioLife Solutions expects total revenue for 2026 to be in the range of $112.5 million to $115 million, representing growth of 17% to 20%.
Gross Margin and Adjusted EBITDA: The company anticipates GAAP and adjusted gross margins for the full year to be in the mid-60s. Adjusted EBITDA margin is expected to expand in 2026 compared to 2025.
GAAP Net Income: BioLife expects to achieve full-year positive GAAP net income for the first time in many years.
Market Trends and Growth Opportunities: The company sees diversification in the cell therapy field beyond oncology into autoimmune indications and solid tumors. Emerging data in allogeneic cell therapies and renewed interest in autologous approaches are expected to unlock multibillion-dollar market opportunities.
Pipeline and Commercial Revenue: BioLife's solutions are utilized in over 250 commercially sponsored CGT clinical trials in the U.S., with a 70% market share. This pipeline is expected to convert into future commercial revenue as therapies advance through the approval process.
Operational Priorities: The company is addressing bag yield dynamics, which are expected to be temporary, and anticipates corresponding gross margin expansion as the issue is resolved.
Strategic Initiatives: BioLife is focused on expanding its role within the CGT workflow, including cross-selling efforts and evaluating acquisitions, minority investments, and strategic partnerships to broaden its platform.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are the margins for bags lower than bottles, and what is the update on the scrap issue tied to the bags?
A:Yes, bags have a lower gross margin than bottles due to yield issues. The company is working with customers to provide alternatives to the problematic bags. A 90-day notification period will follow, and enhanced margins are expected to flow through in Q4 or Q1 of 2027, depending on inventory burn-through.
Q:What is the update on the PanTHERA product and other new products?
A:The PanTHERA product is on track for a Q4 launch with a finalized value proposition and molecule. Other tools are growing at a faster rate than biopreservation media, but cross-selling efforts are a longer-term process due to validation requirements.
Q:What is the impact of biotech funding recovery on BioLife's business?
A:Biotech funding recovery has minimal impact on BioLife as most revenue comes from well-capitalized firms. Early-stage customers affected by funding buy small amounts of products. Biotech financing has stabilized and is not expected to be a headwind.
Q:How is the CryoCase product performing commercially?
A:The CryoCase product has received recognition, including a Best In Show award. Over three dozen validations are ongoing, and traction is expected in the second half of the year, potentially with a notable customer announcement.
Q:What is the status of allogeneic cell therapy and its impact on BioLife?
A:Allogeneic cell therapy is still a couple of years away from having a revenue impact on BioLife. While BPM volumes per patient may be lower, the larger patient populations are expected to outweigh this reduction.
Q:What is the target for GAAP net income?
A:The target for GAAP net income is for the full year per quarter.
Q:Is there an opportunity to capture more share as cell and gene therapy expands into larger indications?
A:Yes, the share of homebrew is decreasing, and the use of standardized platforms is increasing. BioLife is involved in over 900 trials, with 250+ being commercially sponsored, and expects the trend to favor their products.
Q:What is driving the increase in R&D expenses?
A:The increase in R&D expenses is due to the establishment of the Center of Excellence with a team of PhD scientists, investments in internal product development, and projects like the RCC and consumable line for the CT-5.
Q:What is the outlook for commercial BPM customers' revenue contribution?
A:Commercial BPM customers currently contribute about half of the revenue, with a target of 55% for this year. The growth rate of this group suggests a higher contribution in the future.
Q:Are there any synergies expected from the Pluristyx and Qkine agreement?
A:No direct synergies are expected from the Pluristyx and Qkine agreement that would impact BioLife's revenue.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the potential customer pull-through from the Pluristyx and Qkine agreement, stating that it would not directly impact BioLife's revenue without elaborating further.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BPM
CGT
acquisition
activity
adoption
approach
approval
area
balance
bar
biopreservation medium
cell processing
cell therapy
component
demand
driver
dynamic
effort
end market
expansion
funding
indication
investment
landscape
margin
market share
model
nature
opportunity
party
processing tool
product
profile
program
setting
share stage
solution
term
therapy potential
trial
tumor
visibility
BLFS Transcript
BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call reflects a mixed outlook: declining gross margins due to product mix and manufacturing issues, but a positive net income and ongoing product development. The Q&A highlights potential future benefits from new products and market expansion but also indicates current challenges with margins and no immediate synergies from recent agreements. The guidance for 2026 is cautiously optimistic but lacks strong short-term catalysts, resulting in a neutral sentiment for the stock price.
BioLife Solutions, Inc. (BLFS) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary highlights strong financial performance with a 15% revenue increase and improved gross margins. The company has also raised its revenue guidance, indicating confidence in future growth. Despite the absence of details on operational updates and shareholder returns, the positive financial metrics, increased cash flow, and optimistic guidance suggest a favorable outlook. The lack of concerning insights from the Q&A further supports a positive sentiment.
BioLife Solutions, Inc. (BLFS) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call reflects positive sentiment, with raised revenue guidance and improved financial metrics such as GAAP net income and adjusted EBITDA. Despite increased expenses, the company demonstrates strong growth and financial health. The Q&A section supports this with optimistic outlooks for 2026 and no major concerns from analysts. While there are some uncertainties, like the government shutdown, they are already accounted for in the guidance. The focus on growth through commercial customers and the stable funding environment further boosts confidence, indicating a likely positive stock price movement.
BioLife Solutions, Inc. (BLFS) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary shows strong financial performance, with a 33% revenue growth in cell processing and improved EBITDA margin. The acquisition of PanTHERA enhances the company's capabilities. Despite increased operating expenses due to acquisition costs, the adjusted operating loss improved. The Q&A section revealed confidence in future revenue, cross-selling opportunities, and product interest. However, the market cap is unavailable, but given the positive trends and strategic positioning, a positive stock price movement (2% to 8%) is anticipated.
BLFS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
